Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
30 mg/kg 每天 (大鼠);50 mg/kg 每天两次 (小鼠)p.o.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Van Rompaey L, et al. J Immunol. 2013, 191(7), 3568-3577.
分子式 C21H23N5O3S |
分子量 425.5 |
CAS号 1206161-97-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO >80 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT03025308 | RheumatoId Arthritis | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Phase 3 | 2017-02-28 | 2017-03-21 |
NCT02914600 | Crohn's Disease | Drug: Filgotinib|Drug: Placebo | Gilead Sciences|Galapagos NV | Phase 3 | 2017-01-23 | 2017-03-09 |
NCT02914535 | Ulcerative Colitis | Drug: Filgotinib|Drug: Placebo | Gilead Sciences|Galapagos NV | Phase 3 | 2017-01-24 | 2017-03-21 |
NCT03077412 | Fistulizing Crohn's Disease | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Phase 2 | 2017-03-01 | 2017-03-08 |
NCT03046056 | Small Bowel Crohn's Disease | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Phase 2 | 2017-02-01 | 2017-02-06 |
NCT02914561 | Crohn's Disease | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Phase 3 | 2016-10-01 | 2017-03-09 |
NCT02914522 | Ulcerative Colitis | Drug: Filgotinib|Drug: Placebo to match filgotinib | Gilead Sciences|Galapagos NV | Phase 3 | 2016-11-14 | 2017-03-06 |
NCT02873936 | Rheumatoid Arthritis | Drug: Filgotinib|Drug: Placebo to match filgotinib|Drug: csDMARDs | Gilead Sciences|Galapagos NV | Phase 3 | 2016-07-01 | 2017-02-27 |
NCT02886728 | Rheumatoid Arthritis | Drug: Filgotinib|Drug: Placebo to match filgotinib|Drug: MTX|Drug: Placebo to match MTX | Gilead Sciences|Galapagos NV | Phase 3 | 2016-08-01 | 2017-02-27 |
NCT02889796 | Rheumatoid Arthritis | Drug: Filgotinib|Drug: Placebo to match filgotinib|Drug: Adalimumab|Drug: Placebo to match adalimumab|Drug: MTX | Gilead Sciences|Galapagos NV | Phase 3 | 2016-08-01 | 2017-03-03 |
NCT02065700 | Rheumatoid Arthritis | Drug: Filgotinib | Gilead Sciences|Galapagos NV | Phase 2 | 2014-02-01 | 2017-01-12 |
NCT02885181 | Rheumatoid Arthritis | Drug: GS-9876|Drug: Filgotinib|Drug: GS-9876 placebo|Drug: Filgotinib placebo|Drug: Methotrexate | Gilead Sciences | Phase 2 | 2016-09-01 | 2017-03-09 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们